دورية أكاديمية
Salinomycin's potential to eliminate glioblastoma stem cells and treat glioblastoma multiforme (Review).
| العنوان: | Salinomycin's potential to eliminate glioblastoma stem cells and treat glioblastoma multiforme (Review). |
|---|---|
| المؤلفون: | Magrath JW; Department of Chemical and Biological Engineering, The University of Alabama, Tuscaloosa, AL 35487-0203, USA., Kim Y; Department of Chemical and Biological Engineering, The University of Alabama, Tuscaloosa, AL 35487-0203, USA. |
| المصدر: | International journal of oncology [Int J Oncol] 2017 Sep; Vol. 51 (3), pp. 753-759. Date of Electronic Publication: 2017 Jul 27. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9306042 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2423 (Electronic) Linking ISSN: 10196439 NLM ISO Abbreviation: Int J Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2003->: Athens, Greece : D.A. Spandidos Original Publication: Athens, Greece : Lychnia, |
| مواضيع طبية MeSH: | Glioblastoma/*drug therapy , Neoplasm Recurrence, Local/*drug therapy , Neoplastic Stem Cells/*drug effects , Pyrans/*therapeutic use, Brain/drug effects ; Brain/pathology ; Dacarbazine/analogs & derivatives ; Dacarbazine/therapeutic use ; Glioblastoma/pathology ; Humans ; Neoplasm Recurrence, Local/pathology ; Temozolomide |
| مستخلص: | Glioblastoma multiforme (GBM) is the most common and deadliest form of primary brain tumor. Despite treatment with surgery, radiotherapy, and chemotherapy with the drug temozolomide, the expected survival after diagnosis remains low. The median survival is only 14.6 months and the two-year survival is a mere 30%. One reason for this is the heterogeneity of GBM including the presence of glioblastoma cancer stem cells (GSCs). GSCs are a subset of cells with the unique ability to proliferate, differentiate, and create tumors. GSCs are resistant to chemotherapy and radiation and thought to play an important role in recurrence. In order to effectively treat GBM, a drug must be identified that can kill GSCs. The ionophore salinomycin has been shown to kill cancer stem cells and is therefore a promising future treatment for GBM. This study focuses on salinomycin's potential to treat GBM including its ability to reduce the CSC population, its toxicity to normal brain cells, its mechanism of action, and its potential for combination treatment. |
| المشرفين على المادة: | 0 (Pyrans) 62UXS86T64 (salinomycin) 7GR28W0FJI (Dacarbazine) YF1K15M17Y (Temozolomide) |
| تواريخ الأحداث: | Date Created: 20170803 Date Completed: 20180424 Latest Revision: 20181202 |
| رمز التحديث: | 20231215 |
| DOI: | 10.3892/ijo.2017.4082 |
| PMID: | 28766685 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!